Pegargiminase

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Pegargiminase
Accession Number
DB06592
Type
Small Molecule
Groups
Investigational
Description

Pegargiminase is an anticancer agent.

Synonyms
  • ADI-PEG 20
  • Arginine deiminase pegylated
  • Pegargiminase
  • Pegylated arginine deiminase
Categories
UNII
0B7PYQ9YRT
CAS number
1394129-74-8

Pharmacology

Indication

Investigated for use/treatment in melanoma and hepatocellular carcinoma.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Pancreatic Cancer1
1Active Not RecruitingTreatmentGliomas / Hepatocellular Carcinoma (HCC) / Hepatocellular,Carcinoma / Metastatic Uveal Melanoma / Non-Squamous Non-Small Cell Lung Carcinoma / Non-squamous Non-small Cell Lung Carcinoma Stage IIIB/IV (NSCLC) / Peritoneal Mesothelioma Malignant Advanced / Pleural Mesothelioma Malignant Advanced / Sarcomatoid Cancers / Sarcomatoid Carcinoma / Uveal Melanoma1
1CompletedTreatmentArgininosuccinate Synthetase Deficient1
1CompletedTreatmentCutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors1
1CompletedTreatmentHER2 Negative Metastatic Breast Cancer1
1CompletedTreatmentHepatocellular,Carcinoma1
1CompletedTreatmentProstate Cancer / Tumors, Solid1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2CompletedTreatmentMetastatic Melanoma / Neoplasms / Skin Cancers1
2Active Not RecruitingTreatmentAML Subjects Who Have Failed Prior Systemic Therapy / Leukemia Acute Myeloid Leukemia (AML)1
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentNHL Subjects Who Have Failed Prior Systemic Therapy / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentUnresectable Hepatocellular Carcinoma1
2RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Unknown StatusTreatmentMalignant Pleural Mesothelioma (MPM)1
3CompletedTreatmentHepatocellular,Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:39 / Updated on June 04, 2019 06:26